Home

Intelligence

Services

Subscriptions

News

About Us

Sign In

 

Document Preview

Asset Purchase Agreement

 

Click "Add to Cart" button to purchase document. 
Documents are emailed immediately after purchase. 
You can also browse documents by
title, category, or company... or click here for help finding documents.

 

Title:

Asset Purchase Agreement

Entities:

Chase Manhattan Bank; Chase Securities Inc.; Pfizer, Inc.; Phibro Animal Health Corp; PNC Bank, NA; Smithkline Beecham plc; Weil, Gotshal & Manges LLP

Date:

2000

Size:

Preview shows 5KB of 513KB total

Price:

$99

ID:

#1577145

 

 

► Purchase & Sale ► Purchase ► Asset Purchase Agreements
► Miscellany ► Fortune 100
► Financial
► Services ► Legal
► Biotech & Drugs ► Pharmaceutical Preparations

 

 

Start of Preview


                            ASSET PURCHASE AGREEMENT


among

PFIZER INC.,

the

ASSET SELLING CORPORATIONS

(named herein)

and

PHILIPP BROTHERS CHEMICALS, INC.

DATED AS OF SEPTEMBER 28, 2000


TABLE OF CONTENTS

Page

ARTICLE I DEFINITIONS AND TERMS................................................1

Section 1.1 Definitions.............................................1

Section 1.2 Other Definitional Provisions..........................12

ARTICLE II PURCHASE AND SALE..................................................12

Section 2.1 Purchase and Sale of the Conveyed Assets...............12

Section 2.2 Consents...............................................14

Section 2.3 Retained Assets........................................15

Section 2.4 Assumption of Liabilities..............................16

Section 2.5 Retained Liabilities...................................17

Section 2.6 Purchase Price.........................................18

Section 2.7 Purchase Price Adjustment..............................21

Section 2.8 Production Margin Royalty Payments.....................23

Section 2.9 Allocation of the Purchase Price.......................25

ARTICLE III CLOSING...........................................................25

Section 3.1 Closing................................................25

ARTICLE IV CONDITIONS TO CLOSING..............................................26

Section 4.1 Conditions to the Obligations of Purchaser and Pfizer..26

Section 4.2 Conditions to the Obligations of Purchaser.............26

Section 4.3 Conditions to the Obligations of Pfizer................26

ARTICLE V REPRESENTATIONS AND WARRANTIES OF PFIZER............................27

Section 5.1 Organization...........................................27

Section 5.2 Authority; Binding Effect..............................28

Section 5.3 Non-Contravention......................................28

Section 5.4 Pfizer Consents and Approvals..........................29

Section 5.5 Financial Information..................................29

Section 5.6 Absence of Material Changes............................29

Section 5.7 No Litigation..........................................30

Section 5.8 Compliance with Laws...................................30

Section 5.9 Product Registrations; Regulatory Compliance...........30

Section 5.10 Environmental Matters..................................31

Section 5.11 Material Contracts.....................................32


i


TABLE OF CONTENTS
(continued)

Section 5.12 Intellectual Property..................................33

Section 5.13 Real Property..........................................33

Section 5.14 Assets.................................................34

Section 5.15 Employee Benefits......................................34

Section 5.16 No Questionable Payments...............................35

Section 5.17 Major Customers and Suppliers..........................35

Section 5.18 Brokers................................................36

Section 5.19 Taxes..................................................36

ARTICLE VI REPRESENTATIONS AND WARRANTIES OF PURCHASER........................36

Section 6.1 Organization and Qualification.........................36

Section 6.2 Corporate Authorization................................36

Section 6.3 Binding Effect.........................................36

Section 6.4 Non-Contravention......................................37


 

End of Preview

 

Home        Intelligence        Services        Subscriptions        News        About Us

Contact Us       Terms of Use       Resend Documents       Shopping Cart

Copyright © 2008 The Consus Group LLC